[ad_1]
The NT Council recommends the county council to use Ocrevus▼(ocrelizumab) fislandr treatment of primary progressive MS. In forest states, the NT Council encourages county councils to use the most cost-effective treatment. TLV believes that Ocrevus is profitable or economical compared to approved solutions.
The NT Council recommends to the county council that Ocrevus ▼ (ocrelizumab) can be introduced as a treatment option for primary progressive MS and forest SP.
- Ocrevus can be used as a treatment option for a defined group of patients *.
- In forest countries, county councils are recommended to use the most cost-effective treatment among alternatives.
Dental and Pharmaceuticals believes that Ocrevus is profitable compared to a number of relevant alternatives in the forest Member States. For example, Ocrevus is economically regulated and evaluated, and is now available as a new alternative for treating Swedish patients with MS.
"We are very pleased with this recommendation from the NT Council, and Ocrevus has proven successful in global studies of both forest and primary progressive MS, and Ocrevus is approved in 70 countries and more than 70,000 patients. already received treatment, said Margareta Olsson Birgersson, medical director of Roche, Sweden.
"It is positive that we now have another alternative for MS in the forest and that, for the first time, we also have an approved treatment for early primary progressive MS. It's very helpful to have new options that can actually slow down the course of the disease and serve as a treatment for a long time, said Jan Lycke, professor of neurology at the University of Gothenburg and a lecturer at the University of Gothenburg. 39, Sahlgrenska University Hospital.
* Age ≤ 55 years, disease duration ≤ 15 years, EDSS ≤ 6.5, signs of active inflammatory disease by the presence of contrast-contrast lesions on recent MR (approximately 3 months).
About Ocrevus
Ocrevus is a targeted humanized antibody drug designed to specifically target CD20 positive B cells. Ocrevus is designed to be particularly suitable for the long-term treatment of MS and has a low level of antibody formation against the drug. Ocrevus is given by infusion twice a year.
CD20 is a protein found on the surface of the body's B cells, which plays a key role in inflammation that occurs in multiple sclerosis and causes damage to myelin and axons. These injuries cause disability in most people with MS. Clinical studies show that Ocrevus reduces the number of CD20 positive B cells. However, Ocrevus does not affect stem cells or plasma cells, which means that important functions of the immune system are preserved.
For more information
Lotta Luciani, Communications Manager, Roche AB, 073-334 23 13, [email protected]
references
Tip 1.NT: https://janusinfo.se/nationalordnatforfor.4.7c82b0fc1638b8db71b12b21.html
2Dentistry and Drug Rehabilitation: https://www.tlv.se/download/18.15b37133165bb795253817be/1536757705126/bes180903_underlag_ocrevus.pdf
▼This medicine is under increased surveillance. This will allow you to quickly identify new security information. Healthcare professionals are encouraged to report any suspected adverse reactions. The report should be sent to the Swedish Medicines Agency www.lakemedelsverket.se or directly to Roche at [email protected] or by phone at 08 – 726 12 00.
About Roche
Roche is a global pioneer in the field of pharmaceuticals and diagnostics, which aims to advance science to improve people's lives. The combined strength of medications and diagnostics under one roof has made Roche a leader in tailor-made treatment – a strategy to give each patient the appropriate treatment in the best possible way.
Roche is the world's largest biotech company offering differentiated drugs in oncology, immunology, infectious diseases, ophthalmology and central nervous system disorders. Roche is also a world leader in the in vitro diagnosis and diagnosis of tissue cancer and has been offering a broad range of diabetes products since its inception in 1896. Since then Roche has been researching better ways to prevent, diagnose and treat diseases. and contribute sustainably to society. . The company also aims to improve patient access to medical innovations by collaborating with all stakeholders. Thirty drugs developed by Roche are on the World Health Organization (WHO) Model Essential Medicines Lists of Antibiotics, Life-Saving Anti-Malaria Drugs and Anticancer Drugs. For 10 years, Roche has been recognized as a leader in sustainability in the pharmaceutical, biotech and life sciences industries, the Dow Jones Sustainability Index.
The Rochek Group, headquartered in Basel, Switzerland, is present in more than 100 countries and in 2017 employed more than 94,000 people worldwide. In 2017, Roche invested 10.4 billion Swiss francs in R & D and traded 53.3 billion Swiss francs. American Genentech is a full member of the Roche Group. Roche holds a majority stake in the Japanese company Chugai Pharmaceutical. For more information, visit www.roche.com. In Sweden, there are two subsidiaries; Roche Diagnostics Scandinavia AB with 95 employees and Roche AB, which markets and researches pharmaceutical products with 116 employees in 2017. For more information, visit www.roche.se.
Source link
